Tag:
Gedeon Richter
Latest Headlines
Latest Headlines
Mylan aims first Lexapro copy at Forest Labs
Good news for Mylan ( $MYL ), not so good for Forest Laboratories ( $FRX ).
Gedeon Richter, Forest tout promising results from antipsychotic Ph3
Investigators are reporting promising preliminary top-line results from a late-stage study of an experimental antipsychotic being studied by Hungary's Gedeon Richter and Forest Laboratories ( $FRX ).
Promising PhIII antipsychotic data sets stage for Forest app
Forest Laboratories and its Hungarian development partner Gedeon Richter proffered a set of promising pivotal data from their late-stage study of an experimental drug for bipolar disorder.
Hungary mulls R&D rules for drugmakers
Hungary is planning to change write-off rules for R&D costs for pharma firms, according to a draft bill submitted to parliament. And as Reuters notes, drugmakers like Egis and Richter could be
Richter heads west with $331M Grunenthal asset buy
Gedeon Richter has big plans for women's health in Western Europe--and it's snapped up some assets to make those plans a reality. The company has agreed to pay €236.5 million ($331.4 million)
Richter buys PregLem for up to $461M
Richter Group said today that it will buy Switzerland-based women's health company PregLem in a deal worth up to $461 million. PregLem's most advanced product candidate is Esmya for the treatment of
Generics maker picks data management system
Phase Forward's Clintrial has emerged victorious from a competitive product review by Budapest-based generics giant Gedeon Richter. "We look forward to garnering the benefits inherent in greater drug
Schizophrenia drug gets mixed results in IIb
Forest Laboratories and Hungary's Gedeon Richter says that high doses of its antipsychotic drug failed to demonstrate a statistically significant response in a Phase IIb trial, but low doses of
